Dengue vaccines: WHO position paper – September 2018

Weekly epidemiological record

Overview

In accordance with its mandate to provide guidance  to Member States on   health   policy  matters,  WHO  issues  a  series  of  regularly  updated   position papers  on  vaccines  and  combinations  of  vaccines  against diseases that have an international public  health  impact.  These  papers are  concerned   primarily   with   the   use   of  vaccines in large-scale national immunization  programmes.  They  summarize  essential  background  information  on  diseases  and    vaccines  and  conclude  with    the current WHO position on  the  use  of vaccines  worldwide.

The papers are reviewed by external experts and WHO staff, and reviewed and endorsed by the WHO Strategic Advisory Group of Experts (SAGE) on immunization. The GRADE methodology is used to systematically assess the quality of the available evidence. The SAGE decision-making process is reflected in the evidence-to-recommendation tables.

Related materials

Key references to the dengue position paper (2018)

Summary of WHO position paper on dengue vaccines (2018)

Presentation: Summary of key points - WHO position paper on dengue (2018)

Evidence to recommendation Table 1: Consideration of Dengue Vaccine

Evidence to recommendation Table 2: Seroprevalence and screening and vaccination strategy

GRADE TABLE 1a: What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seropositive individuals 9-16 years of age in the first year following vaccination?

GRADE TABLE 1b: What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seronegative individuals 9-16 years of age in the first year following vaccination?

GRADE TABLE 2a: What is the duration of protection/risk in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?

GRADE TABLE 2b: What is the duration of protection/risk in seronegative individuals 9-16 years of age vaccinated with CYD-TDV?

GRADE TABLE 3a: What is the risk of other serious adverse events (non-dengue) in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?

GRADE TABLE 3b: What is the risk of other serious adverse events (non-dengue) in seronegative individuals 9-16 years of age vaccinated with CYD-TDV?

 

 

Editors
World Health Organization
Number of pages
24
Reference numbers
WHO Reference Number: WER No 36, 2018, 93, 457–476